Skip to main content

Table 4 Mean ANC values for planned sampling days in cycle 1 (FAS-As Randomized and FAS-As Treated)

From: Clinical confirmation to demonstrate similarity for a biosimilar pegfilgrastim: a 3-way randomized equivalence study for a proposed biosimilar pegfilgrastim versus US-licensed and EU-approved reference products in breast cancer patients receiving myelosuppressive chemotherapy

Characteristics

Proposed biosimilar pegfilgrastim (APO-Peg) N = 294

US-licensed pegfilgrastim reference product (US-Neulasta®) N = 148

EU-approved pegfilgrastim reference product (EU-Neulasta®) N = 147

Total N = 589

FAS-As Randomized

 Day on which the peak ANC value was reached

  N

294

148

147

589

  Mean (SD)

3.4 (2.3)

3.1 (0.6)

3.1 (1.4)

3.2 (1.8)

  Median

3.0

3.0

3.0

3.0

  Minimum–maximum

1–24

3–9

1–18

1–24

  95% CIs of mean

3.1–3.6

3.0–3.2

2.9–3.4

3.1–3.4

 Peak ANC value (× 109/L)

  N

294

148

147

589

  Mean (SD)

28.4 (9.5)

29.9 (10.2)

28.7 (9.3)

28.9 (9.6)

  Median

27.7

29.4

27.9

28.0

  Minimum–maximum

3.9–60.5

11.3–88.0

5.8–55.9

3.9–88.0

  95% CIs of mean

27.3–29.5

28.3–31.6

27.2–30.2

28.1–29.7

 Day on which the depth of ANC nadir was reached

  N

294

148

147

589

  Mean (SD)

7.1 (1.8)

7.1 (0.6)

7.3 (2.1)

7.1 (1.7)

  Median

7.0

7.0

7.0

7.0

  Minimum–maximum

1–21

6–11

6–21

1–21

  95% CIs of mean

6.9–7.3

7.0–7.2

7.0–7.7

7.0–7.3

 Depth of ANC nadir (× 109/L)

  N

294

148

147

589

  Mean (SD)

0.6 (1.1)

0.4 (0.6)

0.4 (0.7)

0.5 (0.9)

  Median

0.2

0.2

0.1

0.2

  Minimum–maximum

0.0–9.8

0.0–3.4

0.0–6.0

0.0–9.8

  95% CIs of mean

0.4–0.7

0.3–0.5

0.3–0.5

0.4–0.6

 Day on which recovery of ANC was reached

  N

267

136

137

540

  Mean (SD)

9.4 (2.0)

9.5 (2.1)

9.2 (1.0)

9.4 (1.8)

  Median

9.0

9.0

9.0

9.0

  Minimum–maximum

6–25

8–22

8–13

6–25

  95% CIs of mean

9.2–9.7

9.1–9.8

9.0–9.4

9.2–9.5

Characteristics

Proposed biosimilar pegfilgrastim (APO-Peg) N = 298

US-licensed pegfilgrastim reference product (US-Neulasta®) N = 147

EU-approved pegfilgrastim reference product (EU-Neulasta®) N = 147

Total

N = 589

FAS-As Treated

 Day on which the peak ANC value was reached

  N

298

147

144

589

  Mean (SD)

3.4 (2.3)

3.1 (0.5)

3.1 (1.4)

3.2 (1.8)

  Median

3.0

3.0

3.0

3.0

  Minimum–maximum

1–24

3–9

1–18

1–24

  95% CIs of mean

3.1–3.6

3.0–3.2

2.9–3.4

3.1–3.4

Peak ANC value (× 109/L)

  N

298

147

144

589

  Mean (SD)

28.5 (9.6)

29.7 (10.2)

28.8 (9.2)

28.9 (9.6)

  Median

27.7

28.6

28.3

28.0

  Minimum–maximum

3.9–60.5

11.3–88.0

5.8–55.9

3.9–88.0

  95% CIs of mean

27.4–29.6

28.1–31.4

27.3–30.4

28.1–29.7

Day on which the depth of ANC nadir was reached

  N

298

147

144

589

  Mean (SD)

7.1 (2.0)

7.1 (0.6)

7.2 (1.8)

7.1 (1.7)

  Median

7.0

7.0

7.0

7.0

  Minimum–maximum

1–21

6–11

6–21

1–21

  95% CIs of mean

6.9–7.4

7.0–7.2

6.9–7.5

7.0–7.3

Depth of ANC nadir (× 109/L)

    

  N

298

147

144

589

  Mean (SD)

0.6 (1.1)

0.4 (0.6)

0.4 (0.7)

0.5 (0.9)

  Median

0.2

0.2

0.1

0.2

  Minimum–maximum

0.0–9.8

0.0–3.4

0.0–6.0

0.0–9.8

  95% CIs of mean

0.4–0.7

0.3–0.5

0.3–0.5

0.4–0.6

 Day on which recovery of ANC was reached

  N

270

135

135

540

  Mean (SD)

9.4 (2)

9.4 (2.1)

9.2 (1.0)

9.4 (1.8)

  Median

9.0

9.0

9.0

9.0

  Minimum–maximum

6–25

8–22

8–13

6–25

  95% CIs of mean

9.2–9.7

9.1–9.8

9.0–9.4

9.2–9.5